Harrow launched the U.S. commercialization of BYOOVIZ (ranibizumab-nuna). This FDA-approved biosimilar is interchangeable with Genentech's LUCENTIS. The treatment targets conditions such as Neovascular (Wet) Age-Related Macular Degeneration (AMD).
Harrow assumed all U.S. marketing and sales responsibilities from Biogen. The transition stems from an exclusive agreement with the product's developer, Samsung Bioepis.
The launch positions Harrow to compete in the $9 billion U.S. anti-VEGF market. The company provides a cost-effective alternative for retinal specialists. This move significantly expands Harrow's presence in the retinal disease sector.